Cargando…

Magnesium Modifies the Cardiovascular Mortality Risk Associated with Hyperphosphatemia in Patients Undergoing Hemodialysis: A Cohort Study

BACKGROUND: In vitro studies have shown inhibitory effects of magnesium (Mg) on phosphate-induced calcification of vascular smooth muscle cells, raising the possibility that maintaining a high Mg level may be useful for reducing cardiovascular risks of patients with hyperphosphatemia. We examined ho...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sakaguchi, Yusuke, Fujii, Naohiko, Shoji, Tatsuya, Hayashi, Terumasa, Rakugi, Hiromi, Iseki, Kunitoshi, Tsubakihara, Yoshiharu, Isaka, Yoshitaka
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4278867/ https://www.ncbi.nlm.nih.gov/pubmed/25545498 http://dx.doi.org/10.1371/journal.pone.0116273

Ejemplares similares

Thresholds of iron markers for iron deficiency erythropoiesis—finding of the Japanese nationwide dialysis registry
por: Hamano, Takayuki, et al.
Publicado: (2015)

Hypomagnesemia in Type 2 Diabetic Nephropathy: A novel predictor of end-stage renal disease
por: Sakaguchi, Yusuke, et al.
Publicado: (2012)

The Different Association between Serum Ferritin and Mortality in Hemodialysis and Peritoneal Dialysis Patients Using Japanese Nationwide Dialysis Registry
por: Maruyama, Yukio, et al.
Publicado: (2015)

Serum Creatinine Modifies Associations between Body Mass Index and Mortality and Morbidity in Prevalent Hemodialysis Patients
por: Sakao, Yukitoshi, et al.
Publicado: (2016)

Fibroblast growth factor 23 and 25-hydroxyvitamin D levels are associated with estimated glomerular filtration rate decline
por: Hamano, Takayuki, et al.
Publicado: (2013)

Hyperphosphatemia is not significantly associated with increased all-cause mortality in Korean hemodialysis patients
por: Wakasugi, Minako, et al.
Publicado: (2018)

Japanese society for dialysis therapy renal data registry—a window through which we can view the details of Japanese dialysis population
por: Hanafusa, Norio, et al.
Publicado: (2015)

Mineral Metabolism Markers Are Associated with Myocardial Infarction and Hemorrhagic Stroke but Not Ischemic Stroke in Hemodialysis Patients: A Longitudinal Study
por: Tagawa, Miho, et al.
Publicado: (2014)

Early Mortality Was Highly and Strongly Associated with Functional Status in Incident Japanese Hemodialysis Patients: A Cohort Study of the Large National Dialysis Registry
por: Yazawa, Masahiko, et al.
Publicado: (2016)

Correction: Early Mortality Was Highly and Strongly Associated with Functional Status in Incident Japanese Hemodialysis Patients: A Cohort Study of the Large National Dialysis Registry
por: Yazawa, Masahiko, et al.
Publicado: (2016)

Identification of biomarkers for development of end-stage kidney disease in chronic kidney disease by metabolomic profiling
por: Kimura, Tomonori, et al.
Publicado: (2016)

Effects of Magnesium on the Phosphate Toxicity in Chronic Kidney Disease: Time for Intervention Studies
por: Sakaguchi, Yusuke, et al.
Publicado: (2017)

Efficacy of crushed lanthanum carbonate for hyperphosphatemia in hemodialysis patients undergoing tube feeding
por: Kitajima, Yukie, et al.
Publicado: (2011)

Serum phosphate levels modify the impact of parathyroid hormone levels on renal outcomes in kidney transplant recipients
por: Doi, Yohei, et al.
Publicado: (2020)

Chiral amino acid metabolomics for novel biomarker screening in the prognosis of chronic kidney disease
por: Kimura, Tomonori, et al.
Publicado: (2016)

Safety and efficacy of nicotinamide in the management of hyperphosphatemia in patients on hemodialysis
por: Vasantha, J., et al.
Publicado: (2011)

Dose-Response of Tenapanor in Patients With Hyperphosphatemia Undergoing Hemodialysis in Japan—A Phase 2 Randomized Trial
por: Inaba, Masaaki, et al.
Publicado: (2021)

NaPi-IIb Inhibition for Hyperphosphatemia in CKD Hemodialysis Patients
por: Maruyama, Sonomi, et al.
Publicado: (2020)

Gitelman's syndrome with hyperphosphatemia, effectively responding to single oral magnesium oxide administration: A case report
por: Miya, Aika, et al.
Publicado: (2019)

Association of dialysis-related amyloidosis with lower quality of life in patients undergoing hemodialysis for more than 10 years: The Kyushu Dialysis-Related Amyloidosis Study
por: Tsuruya, Kazuhiko, et al.
Publicado: (2021)

Sevelamer carbonate in the treatment of hyperphosphatemia in patients with chronic kidney disease on hemodialysis
por: Savica, Vincenzo, et al.
Publicado: (2008)

Meta-analysis of the efficacy and safety of sevelamer as hyperphosphatemia therapy for hemodialysis patients
por: Zeng, Qian, et al.
Publicado: (2023)

MON-492 A Case of Gitelman’s Syndrome with Hyperphosphatemia That Responded Effectively to Single Oral Administration of Magnesium Oxide
por: Miya, Aika, et al.
Publicado: (2019)

Letter Regarding “Dose-Response of Tenapanor in Patients With Hyperphosphatemia Undergoing Hemodialysis in Japan—A Phase 2 Randomized Trial”
por: Aoki, Yuki, et al.
Publicado: (2022)

Association between Density of Coronary Artery Calcification and Serum Magnesium Levels among Patients with Chronic Kidney Disease
por: Sakaguchi, Yusuke, et al.
Publicado: (2016)

Low erythropoietin levels predict faster renal function decline in diabetic patients with anemia: a prospective cohort study
por: Fujita, Yohei, et al.
Publicado: (2019)

Low calcium dialysate combined with CaCO(3) in hyperphosphatemia in hemodialysis patients
por: GAO, ZHUO, et al.
Publicado: (2013)

Hyperphosphatemia is associated with patency loss of arteriovenous fistula after 1 year of hemodialysis
por: Moon, Ju-Young, et al.
Publicado: (2015)

Calcium Acetate or Calcium Carbonate for Hyperphosphatemia of Hemodialysis Patients: A Meta-Analysis
por: Wang, Yong, et al.
Publicado: (2015)

Intensified treatment of hyperphosphatemia associated with reduction in parathyroid hormone in patients on maintenance hemodialysis
por: Chen, Lan, et al.
Publicado: (2018)

Effects of three blood purification methods on serum fibroblast growth factor-23 clearance in patients with hyperphosphatemia undergoing maintenance hemodialysis
por: MIAO, LI-YING, et al.
Publicado: (2014)

In Reply to “Letter Regarding ‘Dose-Response of Tenapanor in Patients With Hyperphosphatemia Undergoing Hemodialysis in Japan—A Phase 2 Randomized Trial’”
por: Inaba, Masaaki, et al.
Publicado: (2022)

Hidden Hypocalcemia as a Risk Factor for Cardiovascular Events and All-Cause Mortality among Patients Undergoing Incident Hemodialysis
por: Yamaguchi, Satoshi, et al.
Publicado: (2020)

The effects of tenapanor on serum fibroblast growth factor 23 in patients receiving hemodialysis with hyperphosphatemia
por: Block, Geoffrey A, et al.
Publicado: (2019)

Hyperphosphatemia and Cardiovascular Disease
por: Zhou, Chao, et al.
Publicado: (2021)

Non-occlusive Mesenteric Ischemia with Significant Hyperphosphatemia
por: Yamada, Aki, et al.
Publicado: (2022)

Effect of cholecalciferol on serum hepcidin and parameters of anaemia and CKD-MBD among haemodialysis patients: a randomized clinical trial
por: Obi, Yoshitsugu, et al.
Publicado: (2020)

Massive and rapid left ventricular calcification
por: Iwatani, Hirotsugu, et al.
Publicado: (2009)

Hyperphosphatemia and its relationship with blood pressure, vasoconstriction, and endothelial cell dysfunction in hypertensive hemodialysis patients
por: Jung, Jinwoo, et al.
Publicado: (2022)

The management of hyperphosphatemia by lanthanum carbonate in chronic kidney disease patients
por: Shigematsu, Takashi, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_4glrto3tvq0j65d5b1kd1cd2gj